Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DA5221-T2 + DA5221-B1 + DA5221-B2
- Development stage
- Phase 3
- Lead developer
- Dong-A ST
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DA5221-T2 + DA5221-B1 + DA5221-B2 is an investigational **oral combination therapy** for **type 2 diabetes mellitus**, currently in late-stage clinical development. The regimen combines **DA5221-T2**, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with **DA5221-B1** and **DA5221-B2**, with the latter identified as a dipeptidyl peptidase-4 (DPP-4) inhibitor. This combination targets glycemic control in patients inadequately managed with DPP-4 inhibitor dual therapy. The development is led by Dong-A ST, and clinical trials focus on efficacy (HbA1c reduction) and safety in adults with type 2 diabetes[1][2][3][5][7].
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on DA5221-T2 + DA5221-B1 + DA5221-B2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DA5221-T2 + DA5221-B1 + DA5221-B2.